Amlodipine-Benazepril 10mg-20mg Capsules in Healthy Subjects Under Fasting Conditions

Overview

The objective of this study is to compare the rate and extent of absorption of amlodipine-benzazepril 10 mg-20 mg capsules (test) versus Lotrel® (reference), administered as 1 x 10 mg capsule under fasting conditions.

Full Title of Study: “Randomized, 2-Way, Crossover, Bioequivalence Study of Amlodipine-Benazepril 10mg-20mg Capsules and Lotrel® Administered as 1 x 10 mg-20 mg Capsule in Healthy Subjects Under Fasting Conditions.”

Study Type

• Study Type: Interventional
• Study Design
  • Allocation: Randomized
  • Intervention Model: Crossover Assignment
  • Masking: None (Open Label)
• Study Primary Completion Date: May 2004

Detailed Description

Criteria for Evaluation: FDA Bioequivalence Criteria Statistical Methods: FDA bioequivalence statistical methods

Interventions

• Drug: Amlodipine-benazepril 10 mg-20 mg capsules
  • 1 x 10-20 mg
• Drug: Lotrel® 10 mg-20 mg capsule
  • 1 x 10-20 mg

Arms, Groups and Cohorts

• Experimental: Amlodipine Benazepril
  • Amlodipine Benazepril 10mg-20mg Capsule (test) dosed in first period followed by Lotrel® 10mg-20mg Capsule (reference) dosed in second period
• Active Comparator: Lotrel®
  • Lotrel® 10mg-20mg Capsule (reference) dosed in first period followed by Amlodipine Benazepril 10mg-20mg Capsules (test) dosed in second period

Clinical Trial Outcome Measures

Primary Measures

• Cmax – Amlodipine
  • Time Frame: Blood samples collected over 168 hour period
  • Bioequivalence based on Cmax – Maximum observed concentration
• AUC0-inf – Amlodipine
  • Time Frame: Blood samples collected over 168 hour period
  • Bioequivalence based on AUC0-inf – Area under the concentration-time curve from time zero to infinity (extrapolated)
• AUC0-t – Amlodipine
  • Time Frame: Blood samples collected over 168 hour period
  • Bioequivalence based on AUC0-t – Area under the concentration-time curve from time zero to time of last non-zero concentration (per participant)
• Cmax – Benazepril
  • Time Frame: Blood samples collected over 36 hour period
  • Bioequvialence based on Cmax – Maximum observed concentration
• AUC0-inf – Benazepril
  • Time Frame: Blood samples collected over 36 hour period
  • Bioequivalence based on AUC0-inf – Area under the concentration-time curve from time zero to infinity (extrapolated)
• AUC0-t – Benazepril
  • Time Frame: Blood samples collected over 36 hour period
  • Bioequivalence based on AUC0-t – Area under the concentration-time curve from time zero to time of last non-zero concentration (per participant)

Secondary Measures

• Cmax – Benazeprilat
  • Time Frame: Blood samples collected over 36 hour period
  • Cmax – Maximum observed concentration
• AUC0-inf – Benazeprilat
  • Time Frame: Blood samples collected over 36 hour period
  • AUC0-inf – Area under the concentration-time curve from time zero to infinity (extrapolated)
• AUC0-t – Benazaprilat
  • Time Frame: Blood samples collected over 36 hour period
  • AUC0-t – Area under the concentration-time curve from time zero to time of last non-zero concentration (per participant)

Participating in This Clinical Trial

Inclusion Criteria

• Male of non-child-bearing potential female, non-smoker, 18 years of age and older. – Non-child-bearing potential female subjects is defined as follows: – Post-menopausal state: absence of menses for 12 months prior to drug administration or hysterectomy woth bilateral oophorectomy at least 6 months prior to drug administration. – Surgically sterile: hysterectomy, bilateral oophorectomy, or tubal ligation at least 6 months prior to drug administration. – Capable of consent Exclusion Criteria:

• Clinically significant illnesses within 4 weeks prior to the administration of the study medication. – Clinically significant surgery within 4 weeks prior to the administration of the study medication – Any clinically significant abnormality found during medical screening. – Any reason which, in the opinion of the Medical Sub-Investigator, would prevent the subject from participating in the study. – Abnormal laboratory tests judges clinically significant. – Positive testing for hepatitis B, hepatitis C, or HIV at screening. – EGC abnormalities (clinically significant) or vital sign abnormalities (systolic blood pressure lower than 100 ot over 140 nnHg, diastolic blood pressure lower than 60 or over 90 mmHg, or heart rate less that 60 or over 100 bpm) at screening. – BMI ≥ 30.0 – History of significant alcohol abuse within six months prior to the screening visit or any indication of the regular use of more than fourteen units of alcohol per week ( 1 Unit= 150 mL of wine, 360 mL of beer, or 45 mL ot 40% alcohol) or positive alcohol breath test at screening. – History of drug abuse or use of illegal drugs: use of soft drugs (such as marijuana) within 3 months prior to the screening visit or hard drugs( such as cocaine, phencyclidine [PCP] and crack) within 1 year prior to the screening visit or positive urine drug screen at screening. – History of allergic reactions to heparin,amlodipine,benazepril, or other ACE inhibitors, or other related drugs. – Use of any drugs known to induce hepatic drug metabolism (examples of inducers: barbiturates, carbamazepine, phenytoin, glucocorticoids, omeprazole; examples of inhibitors: antidepressant (SSRI), cimetidine, diltiazem, macrolides, imidazoles, neuroleptics, verapamil, fluoroquinolones, antihistamines) within 30 days prior to administration of the study medication. – Use of and investigational drug or participation in an investigational study within 30 days prior to administration of the study medication. – Clinically significant history or presence of any clinically significant gastrointestinal pathology (e.g. chronic diarrhea, inflammatory bowel diseases), unresolved gastrointestinal symptoms (e.g. diarrhea, vomiting), liver of kidney disease, or other conditions known to interfere with the absorption, distribution, metabolism, or excretion of the drug. – Any clinically significant history or presence of clinically significant neurological, endocrinal, cardiovascular, pulmonary, hematologic, immunologic, psychiatric, or metabolic disease. – Use of prescription medication ( including hormone replacement therapy) within 14 days prior to administration of study medication or over-the-counter products (including natural food supplements, vitamins, garlic as a supplement) within 7 days prior to administration of study medication, except for topical products without systemic absorption. – Difficulty to swallow study medication. Subjects who have used tobacco in any form within the 90 days preceding study drug administration – Any food allergy, intolerance, restriction or special diet that, in the opinion of the Medical Sub-Investigator, could contraindicate the subject's participation in this study. – A depot injection or an implant of any drug within 3 months prior to administration of study medication. – Donation of plasma (500 mL) within 30 days prior to drug administration. Donation or loss of whole blood (excluding the volume of blood that will be drawn during the screening procedures of this study) prior to administration of the study medication as follows: – 50 mL to 300 mL of whole blood within 30 days, – 301 mL to 500 mL of whole blood within 45 days, or – more than 500 mL of whole blood within 56 days prior to drug administration. – Consumption of food or beverages containing grapefruit ( e.g. fresh, canned, or frozen) within 7 days prior to administration of the study medication. – Intolerance to venipunctures – Unable to understand or unwilling to sign the Informed Consent Form. – Clinically significant history of angioedema. Subjects with a clinically significant history or active hypotension. Subjects with a significant history of active neutropenia and/or agranulocytosis. – Breast-feeding subject. – Positive urine pregnancy test at screening.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

• Lead Sponsor
  • Teva Pharmaceuticals USA
• Overall Official(s)
  • Richard Larouche, M.D., Principal Investigator, Anapharm